4//SEC Filing
Kelemen Vicki 4
Accession 0001628280-20-016822
CIK 0001213037other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 4:02 PM ET
Size
8.6 KB
Accession
0001628280-20-016822
Insider Transaction Report
Form 4
Kelemen Vicki
Exec. VP and COO
Transactions
- Sale
Common Stock
2020-11-23$18.60/sh−35,321$657,020→ 5,054 total - Exercise/Conversion
Common Stock
2020-11-23$2.48/sh+35,321$87,596→ 40,375 total - Exercise/Conversion
Stock Options
2020-11-23$2.48/sh−35,321$87,596→ 70,641 totalExercise: $2.48Exp: 2029-06-20→ Common Stock (35,321 underlying)
Footnotes (2)
- [F1]The common stock was sold by the reporting person in a series of open market transactions on the transaction date at a weighted average sale price of $18.6014. The range of prices was $18.40 to $19.25. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares sold at each price.
- [F2]35,321 options vested on 6/20/2020.
Documents
Issuer
Cardiff Oncology, Inc.
CIK 0001213037
Entity typeother
Related Parties
1- filerCIK 0001815809
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 4:02 PM ET
- Size
- 8.6 KB